Deer Horn Announces Non-Brokered Private Placement

VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Deer Horn Capital Inc. (CSE:DHC) (OTCBB:GODYF) (the “Company”or “Deer Horn”announces that it intends to raise up to $400,000 by way of a non-brokered private placement (the “Offering”) of up to 800,000 units (“Units”) at a price of $0.50 per Unit.  Each Unit will consist of one common share in the capital of Deer Horn and one-half of one common share purchase warrant (each whole warrant, a “Warrant”).  Each Warrant will be exercisable into one common share for a period of two years at a price of $0.60/share.

In connection with the private placement, the Company may pay a finder's fee consisting of cash, shares and/or warrants to eligible finders as permitted under applicable securities laws and CSE policies.  The proceeds of the private placement will be used for general corporate purposes.

About Deer Horn

Deer Horn Capital is exploring and developing the Deer Horn Property, a rich gold and silver project with high tellurium grades.  The Deer Horn Property, located in north-central British Columbia, has produced positive economics in a Preliminary Economic Analysis and, to our knowledge, hosts Canada’s only NI 43-101 tellurium resource.

Neither the Canadian Securities Exchange nor its regulations services accept responsibility for the adequacy or accuracy of this release.

Forward-looking information
All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.  These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control.  Readers should not place undue reliance on forward-looking statements.  Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated event.

© 2018 GlobeNewswire, Inc. All Rights Reserved.

Read More..

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.

U.S. FDA Approves Gilead Sciences' (Nasdaq: GILD) Antiviral Veklury (remdesivir) for the Treatment of COVID-19